Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis and Parkinson's disease, among others. The Company's NurOwn technology is based on a differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells, MSC-NTF cells, capable of releasing several neurotrophic factors, including Glial-derived neurotrophic factor, Brain-derived neurotrophic factor, Vascular endothelial growth factor and Hepatocyte growth factor, which are critical for the growth, survival and differentiation of developing neurons. NurOwn is in clinical development for the treatment of ALS. It has completed two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center. It has been granted Fast Track designation and Orphan Status.